Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase NA 2Phase 2 2Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Gastrointestinal 3Sarcoma 2Thoracic 1Other solid neoplasm 1NET 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Refractory Solid Tumors 1

Interventions

Pemetrexed 3sacituzumab govitecan 1ribociclib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1encorafenib 1binimetinib 1Vincristine 1Sunitinib 1Sirolimus 1Raltegravir Potassium 1Paclitaxel 1One-Lung Ventilation 1Midazolam 1Leucovorin 1Itraconazole 1Irinotecan 1Immune Checkpoint Inhibitors 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Drug Therapy 1Clinical Trials, Phase I as Topic 1Cetuximab 1Carboplatin 1Bevacizumab 1Anesthesia, General 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Sunitinib × Other solid neoplasm × Clear all
NCT02691793 2022-06-15

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Samsung Medical Center

Phase 4 Completed
1 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡